CoChat

Rapid Diagnosis of a Coronavirus Associated with Severe Acute Respiratory Syndrome (SARS)

Open access
Poon, Leo L M, Wong, On Kei, Luk, Winsie, Yuen, Kwok Yung, Peiris, Joseph S M, Guan, Yi · 2003 · Clinical Chemistry
Cited by 127

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Severe acute respiratory syndrome (SARS) is a recently emerged disease associated with pneumonia in infected patients (1). The disease is unusual in its severity, and patients suffering from this disease do not respond to empirical antimicrobial treatment for acute community-acquired typical or atypical pneumonia (2). By the end of March 2003, a cumulative total of 1622 cases and 58 deaths had been reported from 13 countries (3). The disease is highly infectious, and attach rates >56% have been reported in healthcare workers caring for SARS patients (2). Recently, we identified a novel virus in the family Coronaviridae in SARS patients (4). Of patients from whom paired acute and convalescent sera were available, all had seroconverted or had a greater than fourfold increase in antibody titer to this novel virus (4), suggesting that it plays an important role in the etiology of SARS. Thus, the establishment of a rapid noninvasive test for this virus is a high priority for monitoring and control of this disease. Here, we report a real-time quantitative PCR assay to detect this virus in clinical specimens. Patients with a clinical diagnosis of SARS and admitted in two hospitals in Hong Kong between February 26, 2003, and March 26, 2003, were considered for this study. Inclusion criteria were a fever of 38 °C or higher, cough or shortness of breath, new pulmonary infiltrate(s) on chest radiographs, and either a history of exposure to a patient with SARS or absence of response to empirical antimicrobial coverage for typical and atypical pneumonia. Samples were collected with informed consent. In total, 29 SARS patients with paired sera and nasopharyngeal aspirate (NPA) samples were available for the study. The diagnosis of SARS was confirmed in all patients by the presence of antibodies against the novel coronavirus in the serum (4). The age of these patients ranged from 24 to 71 years [mean (SD), 45.2 (13.9) years], and the male-to-female ratio was 11:18. At the time of submitting this manuscript, one of the patients had died. NPA samples were collected by suction into a disposable aspiration trap containing 3 mL of viral transport medium (containing, per liter, 2 g of sodium bicarbonate, 5 g of bovine serum albumin, 200 μg of vancomycin, 18 μg of amikacin, and 160 U of nystatin in Earle’s balanced salt solution). Total RNA from 140 μL of each NPA sample was extracted with use of a QIAamp Virus RNA Mini Kit (Qiagen), as instructed by the manufacturer, and eluted in 50 μL of buffer. For isolating RNA from stool specimens, 140 μL of viral transport medium containing suspended stool was subjected to the RNA extraction method described above. Ten microliters of eluted RNA was reverse-transcribed by use of 200 U of Superscript II reverse transcriptase (Invitrogen) in a 20-μL reaction containing 0.15 μg of random hexamers, 10 mM dithiothreitol, and 0.5 mM deoxynucleotide triphosphates. FastStart DNA Master SYBR Green I fluorescence reaction (Roche) was used in the PCR assay. Briefly, 2 μL of cDNA was amplified in 20 μL containing, per liter, 3.5 mmol of MgCl2, 0.25 μmol of forward primer (coro3: 5′-TACACACCTCAGCGTTG-3′), and 0.25 μmol of reverse primer (coro4: 5′-CACGAACGTGACGAAT-3′). Reactions were performed in a LightCycler (Roche) with the following conditions: 10 min at 95 °C, followed by 50 cycles of 95 °C for 10 s, 57 °C for 5 s, and 72 °C for 9 s. Plasmids containing the target sequence were used as positive controls. Fluorescence signals from these reactions were captured at the end of the extension step in each cycle. To determine the specificity of the assay, PCR products were subjected to melting curve analysis at the end of the assay (65 to 95 °C; 0.1 °C/s). On the basis of our identified sequences of this virus, a pair of primers expected to amplify a 182-bp region within the RNA-dependent RNA polymerase-encoding sequence of the virus (accession no. AY268070) was used in the assay. The identity of the product was confirmed by sequencing. To determine the dynamic range of real-time quantitative PCR, serial dilutions of plasmid DNA containing the target sequence were made and subjected to the real-time quantitative PCR assay. The assay was able to distinguish 10-fold differences in concentration over a range from 10 to 107, and no signal was observed in the water control (Fig. 1a ). Detection of a novel human coronavirus associated with SARS by real-time quantitative PCR (a), and melting curve analysis of PCR products from clinical samples (b). (a), amplification plot of fluorescence intensity against the PCR cycle. The copy numbers of input plasmid DNA in the reactions are indicated. The x axis denotes the cycle number of a quantitative PCR assay, and the y axis denotes the fluorescence intensity (F1) over the background. (b), melting curve analysis of PCR products from clinical samples. Signals from positive (+ve) samples, negative (−ve) samples, and a water control (water) are indicated. The x axis denot

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1373/49.6.953

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 127

Metadata

Authors
Poon, L. L. M., Wong, O. K., Luk, W., Yuen, K. Y., Peiris, J. S. M., & Guan, Y.
Venue
Clinical Chemistry
Published
2003-06-01
Volume
49
Issue
6
Pages
953-955
ISSN
  • 0009-9147 (ISSN-L)
  • 1530-8561
OpenAlex
W2155583106
Cited by
127
References
1
FWCI
18.35
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.